Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
A4332 Nepicastat (SYN-117) HClSummary: Dopamine-β-hydroxylase inhibitor
-
A4334 AvanafilTarget: Phosphodiesterases (PDEs)Summary: PDE5 inhibitor
-
A4337 CilostazolSummary: PDE3 inhibitor
-
A4338 RivaroxabanTarget: Factor XaSummary: Factor Xa inhibitor
-
A4340 PimobendanTarget: Phosphodiesterases (PDEs)Summary: Selective PDE3 inhibitor.Ca2+ channel sensitizer
-
A4347 Methotrexate2 CitationTarget: Folate AnalogueSummary: Folate antagonist,inhibits DFHR
-
A4349 S- (+)-RolipramSummary: CAMP-specific PDE4 inhibitor
-
A4355 Tosedostat (CHR2797)1 CitationTarget: AminopeptidasesSummary: Aminopeptidase inhibitor
-
A4356 Varespladib (LY315920)Target: PhospholipasesSummary: HnsPLA inhibitor,potent and selective
-
A4358 U-104Target: Carbonic AnhydrasesSummary: CAIX inhibitor